Novavax to Participate in World Vaccine Congress Europe

Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) announced that Dr. Vivek Shinde will present at the World Vaccine Congress Europe 2021 on October 20, 2021. The focus will be on the COVID-NanoFlu™ Combination Vaccine, a novel formulation that integrates the company's COVID-19 and NanoFlu™ vaccine candidates using the Matrix-M™ adjuvant.

The session is scheduled from 11:30 a.m. to 12:00 p.m. CET (5:30 a.m. to 6:00 a.m. EDT). For details, visit the Congress website.

GAITHERSBURG, Md., Oct. 15, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that Vivek Shinde, M.D., Vice President, Clinical Development, will deliver a presentation during the World Vaccine Congress Europe 2021. A topic of discussion will be Novavax' COVID-NanoFlu™ Combination Vaccine, which combines the company's recombinant nanoparticle protein-based COVID-19 and NanoFlu™ vaccine candidates with Matrix-M™ adjuvant in a single formulation.

Session details are as follows:

Date:	Wednesday, October 20, 2021
Time:	11:30 a.m. – 12:00 p.m. Central European Time (CET) / 5:30 a.m. – 6:00 a.m. Eastern Daylight Time (EDT)
Title:	Update on Novavax' NanoFlu vaccine and COVID-19-NanoFlu Combination Vaccine development
Novavax Participant:	Vivek Shinde, M.D., Vice President, Clinical Development

For more information or to register, visit the Congress website.  

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:

Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com

Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com

Media
Ali Chartan | 240-720-7804
Laura Keenan Lindsey | 202-709-7521
media@novavax.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-world-vaccine-congress-europe-301401419.html

SOURCE Novavax, Inc.

FAQ

What is the date of Novavax's presentation at the World Vaccine Congress Europe 2021?

Novavax's presentation is on October 20, 2021.

Who will present Novavax's COVID-NanoFlu Combination Vaccine?

Dr. Vivek Shinde, Vice President of Clinical Development, will present.

What time will the Novavax presentation occur?

The presentation will take place from 11:30 a.m. to 12:00 p.m. CET on October 20, 2021.

What is the focus of Novavax's presentation at the Congress?

The focus will be on the development of the COVID-NanoFlu Combination Vaccine.

Where can I register for the World Vaccine Congress Europe 2021?

You can register by visiting the Congress website.